NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.47 -0.48 (-4.38 %)
(As of 06/21/2018 03:55 PM ET)
Previous Close$10.95
Today's Range$10.35 - $11.02
52-Week Range$7.55 - $14.99
Volume11,587 shs
Average Volume92,820 shs
Market Capitalization$203.62 million
P/E Ratio-23.30
Dividend YieldN/A
Beta-0.16
Fennec Pharmaceuticals logoFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530

Debt

Debt-to-Equity RatioN/A
Current Ratio22.93
Quick Ratio22.93

Price-To-Earnings

Trailing P/E Ratio-23.30
Forward P/E Ratio-25.54
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.68 per share
Price / Book6.23

Profitability

EPS (Most Recent Fiscal Year)($0.47)
Net Income$-7,040,000.00
Net MarginsN/A
Return on Equity-44.03%
Return on Assets-41.44%

Miscellaneous

Employees3
Outstanding Shares18,580,000

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings results on Monday, May, 14th. The company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.03. View Fennec Pharmaceuticals' Earnings History.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Fennec Pharmaceuticals.

What price target have analysts set for FENC?

3 brokers have issued 1-year price objectives for Fennec Pharmaceuticals' shares. Their forecasts range from $17.00 to $22.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $19.00 in the next year. View Analyst Ratings for Fennec Pharmaceuticals.

What are Wall Street analysts saying about Fennec Pharmaceuticals stock?

Here are some recent quotes from research analysts about Fennec Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. " (5/30/2018)
  • 2. HC Wainwright analysts commented, "We remind investors that Fennec has guided towards the completion of the New Drug Application (NDA) submission to the FDA by late this year. In addition, we note that the agency previously granted PEDMARK (a unique formulation of sodium thiosulfate) the prized Breakthrough Therapy Designation (BTD) for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). There are currently no drugs approved in the U.S. for this condition. BTD is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions for which there are no existing effective therapies. Given its Orphan Drug classification, BTD and Fast Track status, along with the unmet need in the pediatric oncology patient population, we continue to believe that PEDMARK could be approved in mid-2019 and launched in the U.S." (5/23/2018)

Who are some of Fennec Pharmaceuticals' key competitors?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the folowing people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

Has Fennec Pharmaceuticals been receiving favorable news coverage?

Press coverage about FENC stock has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also assigned news stories about the company an impact score of 45.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (4.72%). Company insiders that own Fennec Pharmaceuticals stock include Manchester Management Pr, Llc and Spa Essetifin. View Institutional Ownership Trends for Fennec Pharmaceuticals.

Which institutional investors are buying Fennec Pharmaceuticals stock?

FENC stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $10.47.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $203.62 million. The company earns $-7,040,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Fennec Pharmaceuticals employs 3 workers across the globe.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.


MarketBeat Community Rating for Fennec Pharmaceuticals (FENC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.